Expecto Health Science Partners with Neuratrial to Pioneer AI-Driven CRO Operating Model
April 8, 2026 | Wednesday | News
Partnership aims to improve cost-to-deliver, compress timelines, strengthen compliance, and enable faster, evidence-backed decision-making across the clinical development lifecycle
Expecto Health Science, a full-service Asia-Pacific Contract Research Organization (CRO), announced a strategic partnership with Neuratrial, an enterprise AI platform purpose-built for clinical research organizations, to jointly develop and implement an AI-enabled operating model across the clinical research lifecycle.
This partnership is focused on enabling Expecto’s vision of becoming a next-generation, AI-augmented CRO by embedding enterprise AI capabilities across core functions including feasibility, study start-up, clinical operations, medical writing, pharmacovigilance, regulatory documentation, quality processes and more.
This collaboration will focus on deploying governed, enterprise-grade AI designed specifically for clinical research workflows — aimed at improving operational efficiency, optimising time , strengthening audit readiness, and enabling faster, decision-making across project life cycles.
Expecto Health Science brings strong expertise in end-to-end clinical development, regulatory strategy, project management, data management, and functional service provider (FSP) delivery across the Asia-Pacific region. By integrating Neuratrial’s enterprise AI productivity layer, the partnership aims to create a scalable and future-ready clinical delivery model that improves speed, quality, compliance, and efficiency for sponsors.
Dr. Pramod Kashid, CEO of Expecto Health Science, commented:
“The clinical research industry is entering a new era where AI will fundamentally reshape how trials are planned, managed, and delivered. Our partnership with Neuratrial is a strategic step toward building an AI-enabled CRO that can deliver faster timelines, higher quality, and greater operational efficiency for our sponsors.”
Pranab Pillai, Founder & CEO of Neuratrial, added:
“CROs and Sponsors are under increasing pressure to deliver projects faster, without compromising quality, but at the same time bringing in cost efficiency. This partnership with Expecto is about building the next generation CRO. When governed and used appropriately, AI as an enabler will be a gamechanger for teams.”
This strategic collaboration reflects a shared commitment by both organizations to advance clinical research through technology, innovation, and new AI-enables operating models — ultimately getting those medicines to patients faster.